Construction of m6A-Related lncRNA Prognostic Signature Model and Immunomodulatory Effect in Glioblastoma Multiforme.

Xie, Pan; Yan, Han; Gao, Ying; Li, Xi; Zhou, Dong-Bo; Liu, Zhao-Qian

Xie, Pan; Yan, Han; Gao, Ying; Li, Xi; Zhou, Dong-Bo; Liu, Zhao-Qian.

Afiliação

Xie P; Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Yan H; Institute of Clinical Pharmacology, Central South University, Changsha, China.
Gao Y; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Li X; Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Zhou DB; Department of Gerontology, Xiangya Hospital, Central South University, Changsha, China.
Liu ZQ; Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

Front Oncol ; 12: 920926, 2022.

Article em En | MEDLINE | ID: mdl-35719945

Palavras-chave

Glioblastoma multiforme; Immunotherapy; LncRNAs; Prognosis; m6A

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google